Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

“Generation Rx”—Mental Health Watchdog Cautions Against the Boom in Babies Being Given Psychiatric Drugs
  • USA - English


News provided by

Citizens Commission on Human Rights

Jan 28, 2015, 09:00 ET

Share this article

Share toX

Share this article

Share toX


Los Angeles, California (PRWEB) January 28, 2015 -- Mental health watchdog, Citizens Commission on Human Rights, in its latest article, provides the figures on the numbers of babies and young children being given psychiatric drugs. CCHR points out that to comprehend the potential dangers involved in drugging more than a million 0-5 year-olds with these chemicals, one only need consider the expected and limited developmental milestones of these children, which include learning to focus and reaching out and exploring (crawling).[1]

Based on the going rate of drugging, there seems little doubt that an entire generation of America’s children will be given psychiatry’s treatments and branded with the ‘Generation Rx’ moniker.

Post this

CCHR reports the following figures from the IMS Health Vector One National database on the number children 0-5 being given psychiatric drugs:

• Between 2008 and 2013, 0 to 1 year olds made up the largest increase in the number of all psychiatric drugs prescribed and, in that five-year time frame, the prescribing increased 51%.
• In 2013, 274,804 children between the ages of 0-1 had been prescribed an antidepressant, anti-psychotic, anti-anxiety, mood stabilizer or ADHD drug.
• Between 2008 and 2013 there was a 48% increase in the number of 0-5 year-olds prescribed psychiatric drugs.
• In fact, 0-5 year olds represent the largest increase in several individual classes of psychiatric drugs, including a whopping 141% increase in antidepressants, 58% increase in anti-anxiety drugs, and 44% increase in mood stabilizers.
• More than 1 million children aged 0-5 were prescribed psychiatric drugs, with 110,516 taking antidepressants, and 727,304 prescribed anti-anxiety drugs in 2013 alone.[2]

CCHR says that the psychiatric disorders for which these drugs are prescribed are subjective and there is no scientific or medical proof that they exist.[3] Even the director of the National Institute of Mental Health, Dr. Thomas Insel, has no confidence in the legitimacy of psychiatric diagnosing, stating the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) “is, at best, a dictionary, creating a set of labels and defining each.” Insel further explained, “the weakness [of the DSM] is its lack of validity.”[4]

Considering just the prescribing of ADHD drugs, also known as “kiddie cocaine,” CCHR shows that in 2013, more than 10,000 2-3 year olds were taking the drugs.[5] This is despite the fact that the FDA-approved labels for stimulants state, “Long-term effects…in children have not been well established.”[6]

Of greater concern, however, are the known adverse reactions associated with ADHD medications, including agitation, aggressive or hostile behavior, mania, seizures, weight gain, hallucinations, heart problems, stroke and even sudden death. And these are just some of the possible adverse reactions to ADHD drugs.[7]

Antidepressants carry their own set of damaging side effects, including depression, psychosis, mania, hallucinations, agitation, aggression, and suicidal thoughts to name a few.[8] The increased rate of suicidal thoughts and completed suicides associated with antidepressant use forced the FDA to require all antidepressants carry the “black box” warning—the federal agencies most serious warning.[9]

CCHR states that, “Based on the going rate of drugging, there seems little doubt that an entire generation of America’s children will be given psychiatry’s treatments and branded with the ‘Generation Rx’ moniker.”

Read the full article here.

About Citizens Commission on Human Rights: CCHR is a non-profit, non-political, non-religious mental health watchdog. Its mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. CCHR has helped to enact more than 150 laws protecting individuals from abusive or coercive mental health practices.

References:

[1] “Important Milestones: Your Child at One Year,” Centers for Disease Control and Prevention, 27 Mar 2014, cdc.gov/ncbddd/actearly/milestones/milestones-1yr.html; “Important Milestones: Your Baby at Four Months,” Centers for Disease Control and Prevention, 27 Mar 2014, cdc.gov/ncbddd/actearly/milestones/milestones-4mo.html; “Important Milestones: Your Baby at Nine Months,” Centers for Disease Control and Prevention, 27 Mar 2014, cdc.gov/ncbddd/actearly/milestones/milestones-9mo.html.
[2] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Years 2008-2013, Extracted 2014.
[3] Allen Frances, "Psychiatric Fads and Overdiagnosis," Psychology Today, June 2, 2010, psychologytoday.com/blog/dsm5-in-distress/201006/psychiatric-fads-and-overdiagnosis; "Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder," National Institutes of Health Consensus Development Conference Statement, November 16-18, 1998, consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder110html.htm.

[4] Thomas Insel, “Director’s Blog: Transforming Diagnosis,” National Institute of Mental Health, nimh.nih.gov/about/director/2013/transformingdiagnosis.shtml.
[5] IMS, Vector One: National (VONA) and Total Patient Tracker (TPT) Database, Year 2013, Extracted 2014.
[6] “Medication Guide Adderall XR,” Food and Drug Administration, accessdata.fda.gov/drugsatfda_docs/label/2007/021303s015lbl.pdf; Ritalin Drug Label, Food and Drug Administration, accessdata.fda.gov/drugsatfda_docs/label/2007/010187s069,018029s040,021284s011lbl.pdf.
[7] “Dextroamphetamine and Amphetamine,” MedlinePlus, US National Library of Medicine, National Institutes of Health, nlm.nih.gov/medlineplus/druginfo/meds/a601234.html; “Methylphenidate Hydrochloride/Methylphenidate Hydrochloride ER Drug Summary,” Physician’s Desk Reference, pdr.net/drugsummary/methylphenidatehydrochloridemethylphenidatehydrochlorideer?druglabelid=767&id=761; “Methylphenidate,” MedlinePlus, US National Library of Medicine, National Institutes of Health, nlm.nih.gov/medlineplus/druginfo/meds/a682188.html.
[8] Preda A, et al., “Antidepressant associated mania and psychosis resulting in psychiatric admissions,” J Clin Psychiatry, Jan 2001, ncbi.nlm.nih.gov/pubmed/11235925; “Fluoxetine,” MedlinePlus, US National Library of Medicine, National Institutes of Health, nlm.nih.gov/medlineplus/druginfo/meds/a689006.html; “Prozac Drug Summary,” Physician’s Desk Reference, pdr.net/drugsummary/prozac?druglabelid=3205&id=2826.
[9] “Antidepressant Use in Children, Adolescents, and Adults,” Food and Drug Administration, 2 May 2007, fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273.

Media Department, Citizens Commission on Human Rights, http://www.cchrint.org, +1 (323) 467-4242, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.